Trial Profile
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Capecitabine
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Lux
- 01 Sep 2021 Results published in the European Journal of Nuclear Medicine and Molecular Imaging
- 25 Feb 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 20 Apr 2020 Planned End Date changed from 1 Jul 2019 to 1 Jun 2020.